Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) COO Ganesh Venkataraman Kaundinya sold 821 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $13.15, for a total transaction of $10,796.15. Following the transaction, the chief operating officer now owns 487,633 shares in the company, valued at approximately $6,412,373.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Ganesh Venkataraman Kaundinya also recently made the following trade(s):
- On Friday, November 10th, Ganesh Venkataraman Kaundinya sold 392 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.12, for a total transaction of $5,143.04.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded down $0.40 during trading on Monday, reaching $12.55. 697,614 shares of the company were exchanged, compared to its average volume of 616,887. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.90.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The firm had revenue of $24.09 million during the quarter, compared to analyst estimates of $29.58 million. During the same quarter last year, the business posted ($0.26) EPS. The company’s revenue was down 17.3% on a year-over-year basis. analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current fiscal year.
A number of analysts recently weighed in on the stock. ValuEngine cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 6th. BidaskClub cut shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a report on Wednesday, October 4th. Finally, J P Morgan Chase & Co restated a “hold” rating and set a $14.00 target price on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Four equities research analysts have rated the stock with a sell rating and eight have given a hold rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $15.00.
Institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. boosted its stake in shares of Momenta Pharmaceuticals by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 834 shares during the period. Tortoise Investment Management LLC acquired a new stake in shares of Momenta Pharmaceuticals during the 2nd quarter valued at $114,000. Pinebridge Investments L.P. boosted its stake in shares of Momenta Pharmaceuticals by 4.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after buying an additional 363 shares during the period. State of Alaska Department of Revenue boosted its stake in shares of Momenta Pharmaceuticals by 84.6% during the 2nd quarter. State of Alaska Department of Revenue now owns 13,184 shares of the biotechnology company’s stock valued at $222,000 after buying an additional 6,044 shares during the period. Finally, Profund Advisors LLC boosted its stake in shares of Momenta Pharmaceuticals by 13.1% during the 2nd quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 1,530 shares during the period. 93.45% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Insider Selling: Momenta Pharmaceuticals, Inc. (MNTA) COO Sells 821 Shares of Stock” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/04/ganesh-venkataraman-kaundinya-sells-821-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.